葛兰素史克Glaxosmithkline（GSK）2024年年度报告「LSE」（英文版）（344页）.pdf

1、1Inside this reportStrategic report1Ahead Together2Business model42024 performance and keyperformance indicators6Chairs statement8CEOs statement10Our external environment12Research and development32Commercial operations46Responsible business58Our culture and people62Risk management and disclosuresta

2、tements82Group financial reviewCorporate governance113The Board andGSKLeadershipTeam119Chairs governance statement122Corporate governance architecture125Board activities134Board committee reports146Remuneration report176Remuneration policy185Directors reportFinancial statements188Directors statement

3、 of responsibilities190Independent auditors report204 Financial statements208 Notes to the financial statements291Financial statements of GSK plc prepared under UK GAAPInvestor information297Financial record301Product development pipeline307Principal risks and uncertainties319Share capital and contr

4、ol321Dividends322Financial calendar 2025322Annual General Meeting 2025323Tax information for shareholders325Shareholder services and contacts USlaw and regulation330Group companies339Glossary of terms How to navigate this reportPage reference for more information withinthis Annual ReportVisit for mo

5、re information Our supplementsOur Responsible Business Performance Report is available on Front cover image:LungsAs well as supplying vaccines to help protect people from respiratory infections,we are developing treatments that could transform the standard ofcare for people affected by conditions in

6、cluding asthma and chronic obstructive pulmonary disease(COPD).Our pipeline also includes potential new approaches for unmet lung cancer needs.Cautionary statementSee the inside back cover of this document for the cautionary statement regardingforward-looking statements.Non-IFRS measuresWe use a num